Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples

A. Tamás, Andras Javorhazy, D. Reglodi, Donat Peter Sarlos, Daniel Banyai, David Semjen, J. Németh, Beata Lelesz, Daniel Balazs Fulop, Zalan Szanto

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Numerous studies investigated the localization of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in different tumors and described the effects of analogs on tumor growth to show its potential role in oncogenesis. Recently, our research group has found significantly lower levels of PACAP27-like immunorreactivity (LI) and PACAP38-LI in different human samples of primary small cell lung cancer and colon cancer compared to normal healthy tissues. There are only few human studies showing the presence of PACAP and its receptors in urogenital tumors; therefore, the aim of the present study was to compare PACAP-LI in different healthy and pathological human samples from urogenital organs (kidney, urinary bladder, prostate, testis) with radioimmunoassay (RIA) method. Similar to our earlier observations, the PACAP27-LI was significantly lower compared to PACAP38-LI in all samples. We did not find significant alterations in PACAP-LI between healthy and tumoral samples from the urinary bladder and testis. On the other hand, we found significantly lower PACAP38-LI level in kidney tumors compared with healthy tissue samples, and we showed higher PACAP27-LI in prostatic cancer compared to samples from benign prostatic hyperplasia. These data indicate that PACAP levels of different tissue samples are altered under pathological conditions suggesting a potential role of PACAP in the development of different urogenital tumors.

Original languageEnglish
Pages (from-to)177-183
Number of pages7
JournalJournal of Molecular Neuroscience
Volume59
Issue number2
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Neoplasms
Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
Colonic Neoplasms
Testis
Urinary Bladder
Kidney
Small Cell Lung Carcinoma
Prostatic Hyperplasia
Radioimmunoassay
Prostate
Prostatic Neoplasms
Carcinogenesis

Keywords

  • Benign prostatic hyperplasia
  • Kidney
  • PACAP27
  • PACAP38
  • Prostate
  • Urinary bladder radioimmunoassay

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples. / Tamás, A.; Javorhazy, Andras; Reglodi, D.; Sarlos, Donat Peter; Banyai, Daniel; Semjen, David; Németh, J.; Lelesz, Beata; Fulop, Daniel Balazs; Szanto, Zalan.

In: Journal of Molecular Neuroscience, Vol. 59, No. 2, 01.06.2016, p. 177-183.

Research output: Contribution to journalArticle

Tamás, A, Javorhazy, A, Reglodi, D, Sarlos, DP, Banyai, D, Semjen, D, Németh, J, Lelesz, B, Fulop, DB & Szanto, Z 2016, 'Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples', Journal of Molecular Neuroscience, vol. 59, no. 2, pp. 177-183. https://doi.org/10.1007/s12031-015-0652-0
Tamás, A. ; Javorhazy, Andras ; Reglodi, D. ; Sarlos, Donat Peter ; Banyai, Daniel ; Semjen, David ; Németh, J. ; Lelesz, Beata ; Fulop, Daniel Balazs ; Szanto, Zalan. / Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples. In: Journal of Molecular Neuroscience. 2016 ; Vol. 59, No. 2. pp. 177-183.
@article{e006359859384a79ad1c52d4914d3a68,
title = "Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples",
abstract = "Numerous studies investigated the localization of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in different tumors and described the effects of analogs on tumor growth to show its potential role in oncogenesis. Recently, our research group has found significantly lower levels of PACAP27-like immunorreactivity (LI) and PACAP38-LI in different human samples of primary small cell lung cancer and colon cancer compared to normal healthy tissues. There are only few human studies showing the presence of PACAP and its receptors in urogenital tumors; therefore, the aim of the present study was to compare PACAP-LI in different healthy and pathological human samples from urogenital organs (kidney, urinary bladder, prostate, testis) with radioimmunoassay (RIA) method. Similar to our earlier observations, the PACAP27-LI was significantly lower compared to PACAP38-LI in all samples. We did not find significant alterations in PACAP-LI between healthy and tumoral samples from the urinary bladder and testis. On the other hand, we found significantly lower PACAP38-LI level in kidney tumors compared with healthy tissue samples, and we showed higher PACAP27-LI in prostatic cancer compared to samples from benign prostatic hyperplasia. These data indicate that PACAP levels of different tissue samples are altered under pathological conditions suggesting a potential role of PACAP in the development of different urogenital tumors.",
keywords = "Benign prostatic hyperplasia, Kidney, PACAP27, PACAP38, Prostate, Urinary bladder radioimmunoassay",
author = "A. Tam{\'a}s and Andras Javorhazy and D. Reglodi and Sarlos, {Donat Peter} and Daniel Banyai and David Semjen and J. N{\'e}meth and Beata Lelesz and Fulop, {Daniel Balazs} and Zalan Szanto",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s12031-015-0652-0",
language = "English",
volume = "59",
pages = "177--183",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples

AU - Tamás, A.

AU - Javorhazy, Andras

AU - Reglodi, D.

AU - Sarlos, Donat Peter

AU - Banyai, Daniel

AU - Semjen, David

AU - Németh, J.

AU - Lelesz, Beata

AU - Fulop, Daniel Balazs

AU - Szanto, Zalan

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Numerous studies investigated the localization of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in different tumors and described the effects of analogs on tumor growth to show its potential role in oncogenesis. Recently, our research group has found significantly lower levels of PACAP27-like immunorreactivity (LI) and PACAP38-LI in different human samples of primary small cell lung cancer and colon cancer compared to normal healthy tissues. There are only few human studies showing the presence of PACAP and its receptors in urogenital tumors; therefore, the aim of the present study was to compare PACAP-LI in different healthy and pathological human samples from urogenital organs (kidney, urinary bladder, prostate, testis) with radioimmunoassay (RIA) method. Similar to our earlier observations, the PACAP27-LI was significantly lower compared to PACAP38-LI in all samples. We did not find significant alterations in PACAP-LI between healthy and tumoral samples from the urinary bladder and testis. On the other hand, we found significantly lower PACAP38-LI level in kidney tumors compared with healthy tissue samples, and we showed higher PACAP27-LI in prostatic cancer compared to samples from benign prostatic hyperplasia. These data indicate that PACAP levels of different tissue samples are altered under pathological conditions suggesting a potential role of PACAP in the development of different urogenital tumors.

AB - Numerous studies investigated the localization of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in different tumors and described the effects of analogs on tumor growth to show its potential role in oncogenesis. Recently, our research group has found significantly lower levels of PACAP27-like immunorreactivity (LI) and PACAP38-LI in different human samples of primary small cell lung cancer and colon cancer compared to normal healthy tissues. There are only few human studies showing the presence of PACAP and its receptors in urogenital tumors; therefore, the aim of the present study was to compare PACAP-LI in different healthy and pathological human samples from urogenital organs (kidney, urinary bladder, prostate, testis) with radioimmunoassay (RIA) method. Similar to our earlier observations, the PACAP27-LI was significantly lower compared to PACAP38-LI in all samples. We did not find significant alterations in PACAP-LI between healthy and tumoral samples from the urinary bladder and testis. On the other hand, we found significantly lower PACAP38-LI level in kidney tumors compared with healthy tissue samples, and we showed higher PACAP27-LI in prostatic cancer compared to samples from benign prostatic hyperplasia. These data indicate that PACAP levels of different tissue samples are altered under pathological conditions suggesting a potential role of PACAP in the development of different urogenital tumors.

KW - Benign prostatic hyperplasia

KW - Kidney

KW - PACAP27

KW - PACAP38

KW - Prostate

KW - Urinary bladder radioimmunoassay

UR - http://www.scopus.com/inward/record.url?scp=84971268708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971268708&partnerID=8YFLogxK

U2 - 10.1007/s12031-015-0652-0

DO - 10.1007/s12031-015-0652-0

M3 - Article

C2 - 26454744

AN - SCOPUS:84971268708

VL - 59

SP - 177

EP - 183

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 2

ER -